CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will release its third quarter financial results on Tuesday, October 30, 2007 before the market opens. The Company will also hold a conference call on October 30, 2007 at 10:00 a.m. Eastern time to discuss its financial results, the progress of CUDC-101 and other multi-target inhibitors that Curis is developing under its Targeted Cancer Drug Development Platform, Curis’ Hedgehog-based product development programs under collaboration with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
